石斛夜光丸联合重组人表皮生长因子滴眼液治疗干眼症的临床研究  

Clinical study on ShihuYeguang Pills combined with Recombinant Human Epidermal Growth Factor Eye Drops in treatment of xerophthalmia

作　　者：石磊[1] 任睿 唐军峰 安艳芳 杨扬[1] 侯豹可[1] SHI Lei;REN Rui;TANG Jun-feng;AN Yan-fang;YANG Yang;HOU Bao-ke(Department of General Medicine,Jingnan Medical District of PLA General Hospital,Beijing 100036,China)

机构地区：[1]解放军总医院京南医疗区全科医学科,北京100036

出　　处：《现代药物与临床》2022年第12期2808-2811,共4页Drugs & Clinic

基　　金：北京市科技计划项目(Z211100002921049)。

摘　　要：目的 探讨石斛夜光丸联合重组人表皮生长因子滴眼液治疗干眼症的临床疗效。方法 选择2020年1月—2021年6月解放军总医院京南医疗区收治的120例干眼症患者,按照随机数字表法分为对照组和治疗组,每组各60例。对照组外用重组人表皮生长因子滴眼液,直接滴入眼结膜囊内,2~3滴/次,4次/d。在对照组的基础上,治疗组口服石斛夜光丸,7.3g/次,2次/d。两组患者连续治疗7 d。观察两组患者临床疗效,比较治疗前后两组患者症状好转时间,眼底泪膜破裂时间(BUT)、眼底中央泪河高度(TMH)和泪液分泌距离(SIT)水平,及血清因子白细胞介素-6(IL-6)、过氧化脂质(LPO)、超氧化物歧化酶(SOD)和肿瘤坏死因子-α(TNF-α)水平。结果 治疗后,治疗组总有效率(98.33%)明显高于对照组总有效率(83.33%,P<0.05)。治疗后,治疗组患者症状好转时间均明显早于对照组(P<0.05)。治疗后,两组患者BUT、SIT、TMH、SOD水平明显升高,IL-6、LPO和TNF-α水平明显降低(P<0.05),且治疗组BUT、SIT、TMH、IL-6、LPO、SOD和TNF-α水平明显好于对照组(P<0.05)。结论 重组人表皮生长因子滴眼液与石斛夜光丸联合治疗干眼症疗效确切,可有效改善干眼症症状,增加泪液分泌,提高泪膜的保护性,有效降低炎性反应,且安全有效。Objective To investigate the efficacy of ShihuYeguang Pills combined with Recombinant Human Epidermal Growth Factor Eye Drops in treatment of xerophthalmia. Methods Patients(120 cases) with xerophthalmia in Jingnan Medical District of PLA General Hospital from January 2020 to June 2021 were randomly divided into control and treatment group, and each group had 60 cases. Patients in the control group were administered with Recombinant Human Epidermal Growth Factor Eye Drops, dripped directly into the conjunctival sac, 2 — 3 drops/time, four times daily. Patients in the treatment group po administered with ShihuYeguang Pills on the basis of the control group, 7.3 g/time, twice daily. Patients in two groups were treated for 7 d. After treatment, the clinical evaluation was evaluated, the improvement time of symptom, the levels of BUT, SIT, TMH, IL-6, LPO, SOD, and TNF-α in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group(98.33%) was significantly higher than that of the control group(83.33%, P < 0.05). After treatment, the time of symptom improvement in the treatment group was significantly earlier than that in the control group(P < 0.05). After treatment, the levels of BUT, SIT, TMH, and SOD in two groups were significantly increased, while the levels of IL-6, LPO, and TNF-α were significantly decreased in two groups(P < 0.05). The levels of BUT, SIT, TMH, IL-6, LPO, SOD, and TNF-α in the treatment group were significantly better than those in the control group(P < 0.05). Conclusion The combination of Recombinant Human Epidermal Growth Factor Eye Drops and ShihuYeguang Pills is effective in the treatment of xerophthalmia, can effectively improve the symptoms, increase tear secretion,improve the protection of tear film, effectively reduce inflammatory reaction, and which is safe and effective.

关 键 词：石斛夜光丸 重组人表皮生长因子滴眼液 干眼症 眼底泪膜破裂时间 泪液分泌距离 过氧化脂质 

分 类 号：R988.1[医药卫生—药品]